Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.
Saved in:
| Title: | Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. |
|---|---|
| Authors: | Wanner, Christoph1 (AUTHOR) wanner_c@ukw.de, Cooper, Mark E2 (AUTHOR), Johansen, Odd Erik3 (AUTHOR), Toto, Robert4 (AUTHOR), Rosenstock, Julio5 (AUTHOR), McGuire, Darren K4 (AUTHOR), Kahn, Steven E6 (AUTHOR), Pfarr, Egon7 (AUTHOR), Schnaidt, Sven8 (AUTHOR), Eynatten, Maximilian von7 (AUTHOR), George, Jyothis T7 (AUTHOR), Gollop, Nicholas D9 (AUTHOR), Marx, Nikolaus10 (AUTHOR), Alexander, John H11 (AUTHOR), Zinman, Bernard12,13 (AUTHOR), Perkovic, Vlado14 (AUTHOR), investigators, the CARMELINA (AUTHOR) |
| Source: | Clinical Kidney Journal. Jan2021, Vol. 14, p226-236. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20488505 |
|---|---|
| DOI: | 10.1093/ckj/sfaa225 |
